OLE Therapy with The MetaNeb® System for Coronavirus

N/A

Waitlist Available

Research Sponsored by Hill-Rom

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time frame begins when the patient is first started on heated high-flow oxygen therapy and ends when they are ready for discharge from the hospital. expected time is a a few days but not expected to exceed 3 weeks.

Awards & highlights

No Placebo-Only Group

Summary

A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19

Eligible Conditions

Coronavirus
Oscillatory Lung Expansion

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time frame begins when the patient is first started on heated high-flow oxygen therapy and ends when they are ready for discharge from the hospital. expected time is a a few days but not expected to exceed 3 weeks.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time frame begins when the patient is first started on heated high-flow oxygen therapy and ends when they are ready for discharge from the hospital. expected time is a a few days but not expected to exceed 3 weeks.

This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame begins when the patient is first started on heated high-flow oxygen therapy and ends when they are ready for discharge from the hospital. expected time is a a few days but not expected to exceed 3 weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hospital Length of Stay

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: OLE Therapy with The MetaNeb® SystemExperimental Treatment1 Intervention

Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.

Group II: Control GroupActive Control1 Intervention

The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MetaNeb® System

2016

N/A

~420

Do I qualify?Apply below to find out